Adding Lenvatinib to Pembrolizumab Does Not Provide Additional Benefit in Patients with Unresectable Advanced Melanoma By Ogkologos - September 10, 2025 593 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the LEAP-003 study Source RELATED ARTICLESMORE FROM AUTHOR ESMO contributes to discussions on the future of cancer care at EU Cancer Mission event Multicancer early detection test detects tumour-derived cfDNA and demonstrates robust performance characteristics with a favourable safety profile Anito-cel, a d-Domain BCMA CAR T-Cell, Induces Rapid, Deep, and Durable Responses in Patients with Heavily Pretreated Relapsed or Refractory Multiple Myeloma MOST POPULAR Adding Retifanlimab To First-Line Chemotherapy for Patients with Advanced Squamous Cell... July 15, 2025 EMA Recommends Refusal of the Marketing Authorisation for Tagraxofusp August 13, 2020 Alex Trebek Gets Choked Up Seeing Contestant’s Heartfelt ‘Guess’ As Final... November 14, 2019 Multiple Myeloma Awareness Month: Inequity and Disparities in Multiple Myeloma Diagnosis,... March 1, 2021 Load more HOT NEWS Woman Suffers Seizure And Dies After Making Fatal Error With Her... Multipronged Approach Eliminates Racial Disparities in Early-Stage Lung Cancer Treatment Pembrolizumab May Help Prevent Early-Stage Melanoma from Returning Cetuximab Outperforms Durvalumab for Head and Neck Cancer When Cisplatin Isn’t...
